Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesClinical/Medical PolicyHAP AAT deficiency Prior Auth Policy Update | Open…
    Ask Trek AI about this page
    CurrentHealth Alliance Plan (HAP)Policy N/A

    Alpha-1 Antitrypsin (AAT) deficiency therapies prior authorization

    Customize your policy alerts

    Sign up for all Health Alliance Plan (HAP) policy alerts

    Know when Health Alliance Plan (HAP) releases new policies or updates existing guidance.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Defines prior authorization requirements for AAT augmentation products (ARALAST NP, GLASSIA, PROLASTIN-C, ZEMAIRA) including required clinical information, prescriber restrictions, and coverage duration for Health Alliance Plan members.

    Policy Summary
    PayerHealth Alliance Plan (HAP)
    PolicyAAT deficiency therapies prior authorization
    Policy CodePolicy N/A
    Change TypeNo material changes
    Effective DateAug 1, 2026
    Next Review DateN/A
    Key ActionSubmit prior authorization with diagnosis, weight, A1-PI phenotype and baseline A1-PI level; prescription must be written by a pulmonologist.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    4products listed for AAT deficiency
    1 yearcoverage duration for AAT augmentation
    pulmonologistrequired prescriber specialty
    8/1/2026policy effective date

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    Coverage Criteria and Product-Specific Prior Authorization

    Initial authorization criteria

    Covered when ALL of the following are met

    AAT augmentation baseline criteria: Diagnosis of severe congenital A1-PI deficiency with clinically evident emphysema; documentation of patient weight; A1-PI phenotype; baseline A1-PI level

    Prescriber must be a pulmonologist; coverage duration 1 year

    Akeega (selected criteria)

    Covered when ALL of the following are met

    Diagnosis: Member must have metastasis from malignant tumor of the prostate that is castration-resistant with a deleterious or suspected deleterious BRCA mutation
    Age: Beneficiary is of appropriate age for use per FDA prescribing information
    Prescriber: Prescription must be written by an Oncologist or Urologist
    Coverage duration: Approve for up to 5 years

    ALK-positive tyrosine kinase inhibitors (class-level)

    Covered when ALL of the following are met

    Products: Alecensa, Xalkori (capsule/pellet), Zykadia
    Prescriber: Prescribed by an oncologist
    Coverage duration: Approve for up to 5 years

    Alunbrig

    Covered when ALL of the following are met

    Diagnosis: Metastatic non-small cell lung cancer (NSCLC) that is ALK-positive as detected by an approved test
    Prescriber: Prescribed by or in consultation with an oncologist
    Coverage duration: Approve for up to 5 years; continuation of prior therapy allowed

    Firdapse (amifampridine)

    Covered when ALL of the following are met

    Diagnosis: Documented diagnosis of Lambert–Eaton myasthenic syndrome confirmed by electrodiagnostic studies including repetitive nerve stimulation and anti‑P/Q‑type VGCC antibody testing
    Prescriber: Prescription must be written by a neurologist
    Coverage duration: Approve for 1 year

    Analeptic (armodafinil, modafinil)

    Covered when ALL of the following are met

    Products: Armodafinil and modafinil (oral tablets)
    Age: Beneficiary is of appropriate age for use per FDA prescribing information

    Antidepressants (selected)

    Covered when ALL of the following are met

    Products: Auvelity, Fetzima, Trintellix, vilazodone
    Documentation: Diagnosis and prior therapies tried and failed; for MDD must have tried two generic antidepressants from different classes
    Coverage duration: Approve for up to 5 years

    Antipsychotics (selected)

    Covered when ALL of the following are met

    Products: Asenapine maleate, Caplyta, Fanapt, Rexulti, Secludo, Versacloz, Vraylar
    Documentation: Diagnosis and treatment history; for bipolar disorder or schizophrenia, failure with two atypical antipsychotics or rationale why alternatives are not suitable; for MDD with adjunct antipsychotic, trial of one generic antidepressant plus specified atypicals or rationale
    Coverage duration: Approve for up to 3 years

    Aprepitant

    Covered when ALL of the following are met

    Indication: Use with highly- or moderately-emetogenic chemotherapy with chemotherapy regimen (drug, dose, frequency) provided

    When used for PONV provide rationale why preferred agent ondansetron not used

    Coverage duration: Approve for 6 months

    Arcalyst

    Covered when ALL of the following are met

    Products: Arcalyst
    Age: Beneficiary is of appropriate age for use per FDA prescribing information
    Coverage duration: Approve 1 year at a time

    ARCALYST

    ARCALYST — product-level PA summary

    ARCALYST PA requirements: Coverage for Arcalyst requires prior authorization with coverage granted 1 year at a time; beneficiary must be of appropriate age per FDA labeling; indications: all medically-accepted indications; no prerequisite therapy or prescriber restrictions noted.

    Exclusion Criteria: N/A; Required Medical Information: N/A

    ARIKAYCE

    ARIKAYCE — product-level PA criteria

    ARIKAYCE initial PA criteria: Submit medical records supporting the request including sputum culture confirming Mycobacterium avium complex (MAC) lung disease; prescriber must be infectious disease specialist or pulmonologist or in consultation; beneficiary age per FDA labeling; initial review requires documentation of failure to obtain negative sputum cultures after >=6 months of a multidrug background regimen; coverage duration 1 year.>=6 months of background therapy

    Exclusion Criteria: N/A

    ATTRUBY

    ATTRUBY — product-level PA summary

    ATTRUBY PA requirements: Confirmation of diagnosis with appropriate testing is required; prescription must be written by a cardiologist; coverage duration 1 year; indications: all medically-accepted indications.

    Exclusion Criteria: N/A

    AYVAKIT

    AYVAKIT — product-level PA summary

    AYVAKIT PA requirements: Prescription must be written by an oncologist, gastroenterologist, or allergist/immunologist as appropriate; coverage duration 5 years; for GIST require documentation of PDGFRA exon 18 or D842V mutation; for AdvSM require platelet count >50 x10^9/L; indications: all medically-accepted indications.platelets >50 x10^9/L for AdvSM

    Exclusion Criteria: N/A

    Oncology agents

    Selected oncology products — product-level PA summaries

    AVMAPKI-FAKZYNJA PA requirements: Prescription must be written by an oncologist; coverage duration 5 years; indications: all medically-accepted indications.

    Required Medical Information: Diagnosis

    BALVERSA PA requirements: Prescription must be written by an oncologist; coverage duration 5 years; indications: all medically-accepted indications.

    Required Medical Information: Diagnosis

    BALVERSA (example)

    Product-specific PA criteria examples (partial list from this document segment):

    BALVERSA requirements: Prescription must be written by an oncologist; coverage duration 5 years; indications: all medically-accepted indications

    Exclusion criteria: N/A; Part B prerequisite: No

    BENLYSTA SUBCUTANEOUS

    BENLYSTA SUBCUTANEOUS requirements: Prescriber must be a rheumatologist or nephrologist; coverage duration 3 years; required medical information includes diagnosis, autoantibody testing, prior treatments and response (failed two standard therapies at recommended doses)

    Exclusions include severe active lupus nephritis and active central nervous system involvement; Part B prerequisite: No; Prerequisite Therapy: Yes

    BOSULIF

    BOSULIF requirements: Required medical information: diagnosis, prior therapy used and result; for continuation, prior response to bosutinib and CBC and LFT lab results; prerequisite therapy: Yes

    Part B prerequisite: No; Exclusion criteria: N/A

    BRAFTOVI

    BRAFTOVI requirements: Prescription must be written by an oncologist; coverage duration 5 years; indications: all medically-accepted indications

    Part B prerequisite: No; Exclusion criteria: N/A

    BRIVIACT

    BRIVIACT requirements: Required medical information includes response to brivaracetam; beneficiary age per FDA labeling; prerequisite therapy: Yes

    Part B prerequisite: No; Exclusion criteria: N/A

    BONSITY

    BONSITY requirements: Required medical information: diagnosis, fracture history, prior therapy and response; required pretreatment testing including DXA and labs; prescriber must be an endocrinologist; coverage duration 2 years; documentation of trial on an oral or parenteral bisphosphonate required

    Exclusion: not approved in combination therapy with other osteoporosis agents

    COBENFY — Initial coverage

    COBENFY (and COBENFY STARTER PACK) coverage requires:

    COBENFY coverage requirements: Documentation of diagnosis and treatment history; beneficiary age appropriate per FDA labeling; prerequisite therapy required where specified

    Coverage duration 5 years

    COMETRIQ — Initial coverage

    COMETRIQ coverage requires:

    COMETRIQ coverage requirements: Diagnosis documented; prescription written by an oncologist

    Coverage duration 5 years

    COPIKTRA — Initial coverage

    COPIKTRA coverage requires:

    COPIKTRA coverage requirements: Diagnosis documented; prescribed by an oncologist or hematologist

    Coverage duration 5 years

    CORLANOR — Initial coverage

    CORLANOR coverage (for heart failure in adults) is provided when ALL of the following are met:

    Corlanor heart failure criteria: Left ventricular ejection fraction ≤35% AND heart rate ≥70 beats per minute AND in sinus rhythm AND on maximally tolerated beta-blocker OR has contraindication to beta-blockerEF ≤35%; HR ≥70 bpm

    Prescribed by a cardiologist; coverage duration 12 months

    COSENTYX — Initial coverage and step therapy

    COSENTYX coverage requires:

    Cosentyx baseline requirements: Diagnosis and other treatments tried with reasons for failure; baseline and ongoing TB monitoring; prescriber is a rheumatologist or dermatologist

    Coverage duration 1 year; must not be used in combination with other biologic drugs or JAK inhibitors

    Cosentyx disease-specific step therapy: Arthritis: trial of or contraindication to one non-biologic DMARD. Plaque psoriasis: trial and failure of cyclosporine and methotrexate for ≥3 months. Hidradenitis suppurativa: trial of one other therapy.

    Every two-week dosing requires failure of every four-week dosing

    CRESEMBA — Initial coverage

    CRESEMBA ORAL coverage requires:

    CRESEMBA requirements: Beneficiary of appropriate age per FDA labeling; diagnosis documented; prerequisite therapy indicated where specified

    Prior authorization required

    CYCLOBENZAPRINE — Initial coverage

    CYCLOBENZAPRINE coverage requires:

    Cyclobenzaprine requirements: Medical records documenting diagnosis; patients <65 years approved; patients ≥65 years must meet additional criteriaAge <65 vs ≥65

    Coverage duration 1 year

    cyclobenzaprine

    cyclobenzaprine coverage conditions: Medical records documenting diagnosis; patients aged <65 years are approved; patients aged >=65 years require other criteriaage <65

    coverage duration 1 year

    Cystadrops

    Cystadrops coverage conditions: Diagnosis documentation required; beneficiary appropriate age per FDA; prescriber must be an ophthalmologist or corneal specialist; documentation of corneal cystine crystal to start treatmentper FDA age appropriateness

    Daurismo

    Daurismo coverage conditions: Diagnosis documentation required; prescription must be written by an oncologist or hematologist

    Coverage duration 5 years

    Daybue

    Daybue coverage conditions: Diagnosis documentation required; beneficiary age per FDA prescribing informationper FDA age appropriateness

    Demser (metyrosine)

    Demser coverage conditions: Diagnosis and documentation of surgical candidacy required

    Coverage duration 1 year

    Diabetic supplies

    Diabetic supplies coverage conditions: Prescriber must confirm that the supply is requested for use directly associated with delivering insulin

    Coverage duration 1 year

    Diacomit

    Diacomit coverage conditions: Beneficiary appropriate age per FDA; there is no clinical data to support use of Diacomit alone to treat Dravet syndromeper FDA age appropriateness

    Fidaxomicin (Dificid)

    Fidaxomicin coverage conditions: Diagnosis of Clostridioides difficile required; must be prescribed by or in consultation with an infectious disease specialist

    Coverage duration 1 month

    fidaxomicin

    fidaxomicin

    fidaxomicin PA: Prescribed by or in consultation with an infectious disease specialist AND diagnosis of Clostridioides difficile infectioncoverage duration 1 month

    Exclusion criteria: N/A

    DOPTELET

    DOPTELET

    DOPTELET PA for chronic liver disease-associated thrombocytopenia: Diagnosis and platelet count documented AND patient scheduled for a pre-planned medical or dental procedure with treatment beginning 10 to 13 days prior to procedure and procedure performed 5 to 8 days after last dosecoverage duration 1 month (chronic liver disease) or 6 months (chronic ITP)

    Prescribed by appropriate specialist

    DUPIXENT

    DUPIXENT

    DUPIXENT PA general: Prescribed by specified specialist AND beneficiary age appropriate per FDA labeling AND required diagnosis-specific documentation providedcoverage duration 1 year

    Must not be used with other biologic drugs; prior therapy trials required per indication

    DUVYZAT

    DUVYZAT

    DUVYZAT PA: Genetically confirmed diagnosis of Duchenne muscular dystrophy AND baseline function tests documented AND prescribed by or in consultation with an experienced specialistcoverage duration 1 year

    Patient must be ambulatory upon initiation

    Dronabinol

    Dronabinol (oral capsule)

    dronabinol PA: Diagnosis, previous treatments and outcomes documented; for cancer-related weight loss must have treatment failure or intolerance to megestrolcoverage duration 1 year

    Not covered for treatment of pain

    Product-specific PA / prerequisite criteria (multiple)

    Per-product PA and prerequisite therapy requirements (examples captured below):

    Epidiolex PA criteria: Requires diagnosis, prior therapy used and results; if continuation, documentation of response to treatment; prescriber must be or consult with a neurologist for initial prescription

    Coverage duration: 5 years; specific trials required by syndrome (Lennox‑Gastaut, Dravet).

    Dihydroergotamine nasal: Requires diagnosis, prior treatments and responses; prescriber restriction to headache/pain specialist or neurologist; for migraine, trial and failure of two different triptans (one oral tablet and one other formulation) required unless contraindicated

    Coverage duration 1 year

    Erivedge: Exclusion: patients who are candidates for surgery or radiation; prescriber must be an oncologist or dermatologist; coverage duration 5 years
    Various listed products:

    ERIVEDGE

    ERIVEDGE (partial)

    ERIVEDGE coverage: Prior authorization required; diagnosis must be provided; exclusion: patients who are candidates for surgery or radiation; prescriber must be an oncologist or dermatologist; coverage duration 5 years; indications: all medically-accepted indications.

    ERLEADA

    ERLEADA (partial)

    ERLEADA coverage: Prior authorization required; must document diagnosis, prior therapies tried and outcome, fall risk assessment, and seizure history; prescriber must be an oncologist or urologist; coverage duration 1 year; for metastatic CRPC/CSPC patient must have failure/intolerance/contraindication to abiraterone prior to ERLEADA.

    Erythropoiesis Stimulating Agents

    Erythropoiesis Stimulating Agents (ARANESP, EPOGEN) (partial)

    ESA initiation criteria: Prior authorization required; exclusion: uncontrolled hypertension and pure red cell aplasia after ESA; required pre-treatment hemoglobin <10 g/dL AND adequate iron stores (ferritin >100 mcg/L or TSAT >20%); alternative causes of anemia ruled out; prescriber restrictions depend on indication; coverage duration 1 year.Hb <10 g/dL; ferritin >100 mcg/L or TSAT >20%

    EXXUA

    EXXUA (partial)

    EXXUA coverage: Prior authorization required; diagnosis and prior therapies tried and failed required; for MDD must have tried two generic antidepressants including vilazodone; coverage duration 5 years

    FASENRA

    FASENRA (partial)

    FASENRA coverage: Prior authorization required; prescriber must be pulmonologist, immunologist, allergist, or rheumatologist; required documentation includes allergen test, baseline and post-bronchodilator FEV1, asthma history, and baseline eosinophil count; patient must have severe asthma receiving inhaled and/or oral corticosteroids AND baseline eosinophils >=150 cells/mcL within previous 12 months; coverage duration 1 year; must not be used with other biologics.eosinophils >=150 cells/mcL

    FILSUVEZ / FINTEPLA

    FILSUVEZ / FINTEPLA (partial)

    FILSUVEZ/FINTEPLA coverage: Prior authorization entries list product name and that indications are all medically-accepted; beneficiary must be of appropriate age per FDA; no other specifics in these chunks

    FORTEO

    FORTEO (teriparatide) (partial)

    FORTEO coverage: Prior authorization required; exclusion: not approved in combination with other PTH/PTHrP analogs or other osteoporosis agents; required documentation includes diagnosis, fracture history, prior therapies and responses, DXA if not within 2 years and baseline labs; prescriber must be an endocrinologist; coverage duration 2 years; requires trial and failure on oral (or parenteral if intolerant) bisphosphonate AND trial and failure on denosumab.

    FOTIVDA

    FOTIVDA (partial)

    FOTIVDA coverage: Required medical information: diagnosis, prior therapy used and result; if continuation, document response to tivozanib; beneficiary appropriate age per FDA; prerequisite therapy as specified

    Product-specific PA criteria (excerpt)

    Coverage criteria and restrictions as listed per product

    FRUZAQLA: Diagnosis of metastatic colorectal cancer previously treated with fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy and an anti-VEGF therapy (and anti-EGFR if RAS wild-type); prescriber must be or consult with hematologist/oncologist; coverage duration 5 years; prerequisite therapy required
    FYCOMPA (perampanel): Diagnosis must be provided; prescription by a neurologist; monitor for serious psychiatric/behavioral reactions with documentation; coverage duration 5 years
    GATTEX: Required documentation: diagnosis and prior therapies; adults: full colonoscopy with removal of polyps prior to initiation and documentation required; coverage duration 3 years; discontinue therapy in cases of intestinal malignancy
    Gaucher's disease treatments (CERDELGA, miglustat): Not approved for type II or III Gaucher's disease for miglustat; provide diagnosis and rationale why ERT is not appropriate for miglustat; prescriber must be geneticist/hematologist/hepatologist or metabolic specialist; coverage duration 3 years

    GILOTRIF (example product entry)

    Coverage and PA elements for GILOTRIF as presented in the excerpt

    GILOTRIF PA requirements: Prior authorization required; required medical information: diagnosis; prescription must be written by an oncologist; coverage duration 5 years; indications: all medically-accepted indications

    Exclusion Criteria: N/A; Part B prerequisite: No; Prerequisite Therapy: No

    TRULICITY (example product entry)

    Coverage and PA elements for TRULICITY as presented

    TRULICITY PA requirements: Documented diagnosis of type 2 diabetes and submitted A1C from past 6 months required; coverage duration 1 year; exclusion: not covered for weight loss; prerequisite therapy as specified for indications such as cardiovascular risk reduction

    Indications: all medically-accepted indications

    HADLIMA and other biologics (example biologic entry)

    General biologic PA elements and prerequisites

    Biologic PA requirements: PA criteria present; required medical information includes diagnosis, concurrent medications, and prior therapies tried; prescriber restrictions specialty-dependent (eg, rheumatologist, dermatologist); coverage duration 1 year; must not be used in combination with other biologic drugs or JAK inhibitors; step therapy requirements vary by indication

    Specific requirements vary by product and indication

    This section summarizes the general coverage criteria applied across product entries in this segment. Where specified, prior authorization (PA) is required and approval is contingent on submission of documented diagnosis and supporting clinical information appropriate to the requested therapy (for example, phenotype and baseline A1‑PI level for AAT augmentation products). Prescriber restrictions apply when noted (e.g., pulmonologist for AAT augmentation products). Coverage durations are product-specific and commonly set at 1 year for many agents in this excerpt (some oncology and specialist agents list longer durations). Many entries explicitly state Exclusion Criteria: N/A, indicating no additional exclusions are documented in those product-level blocks, while select products list specific exclusions (see product-level entries).

    Numerous product entries in this document excerpt explicitly show that off‑label uses or other exclusion lists are not applicable by marking related fields as N/A. Examples include oncology, neurologic, and behavioral health product entries where the 'Off‑Label Uses' or 'Exclusion Criteria' fields are recorded as N/A. Providers should therefore rely on the individual product PA criteria and required documentation fields when evaluating coverage rather than assuming additional off‑label restrictions unless a specific product entry states otherwise.

    Multiple product entries within this segment explicitly state Exclusion Criteria: N/A, indicating there are no product‑specific exclusions documented in those blocks. This is visible for several agents (for example, ARCALYST, ARIKAYCE, ATTRUBY, AYVAKIT, BALVERSA) where the PA summary lists required medical information and prescriber or duration attributes but records no exclusions. Where exclusions are present for particular products elsewhere in the policy, those are captured in the individual product entries and should be followed; absence of exclusions here does not alter product‑specific exclusions found in other parts of the policy.

    Actions Required by Prescribers / Denial Risks

    Prior Authorization

    Prior authorization required for AAT augmentation products

    Prior authorization is required for ARALAST NP, GLASSIA, PROLASTIN‑C, and ZEMAIRA; the prescription must be written by a pulmonologist and include documentation of diagnosis of severe congenital A1‑PI deficiency with clinically evident emphysema, patient weight, A1‑PI phenotype, and baseline A1‑PI level. Coverage is authorized for 1 year.

    • Prescriber must be a pulmonologist.
    • Include diagnosis, weight, A1‑PI phenotype, and baseline A1‑PI level.
    Documentation Required

    Prescriber must be a pulmonologist

    The prescriber must be a pulmonologist for AAT augmentation product requests; prescriptions from other specialties risk denial for failure to meet the prescriber restriction.

    Affected Products and Coding

    Products Affectedmixed
    ARALAST NPProduct affected
    GLASSIAProduct affected
    PROLASTIN-C INTRAVENOUS SOLUTIONProduct affected
    ZEMAIRAProduct affected
    Products Affected (BOSULIF)mixed
    BOSULIF ORAL CAPSULE 100 MG, 50 MGProduct presentation listed
    BOSULIF ORAL TABLET 100 MG, 400 MG, 500 MGProduct presentation listed
    Products Affected (BRIVIACT)mixed
    brivaracetam oral solutionProduct presentation listed
    brivaracetam oral tabletProduct presentation listed
    Products Affectedmixed
    cyclobenzaprine oral tablet 10 mg, 5 mglisted product
    Products Affectedmixed
    CYSTADROPSlisted product
    Products Affectedmixed
    DAURISMO ORAL TABLET 100 MG, 25 MGlisted product
    Products Affectedmixed
    DAYBUElisted product
    Products Affectedmixed
    metyrosinelisted product (Demser)
    Diabetic suppliesmixed
    alcohol padsdiabetic supply
    GAUZE PADS 2 X 2diabetic supply
    INSULIN PEN NEEDLEdiabetic supply
    INSULIN SYRINGE (DISP) U-100 0.3 ML 29 GAUGE, 1 ML 29 GAUGE X 1/2", 1/2 ML 28 GAUGEdiabetic supply
    NEEDLES, INSULIN DISP.,SAFETYdiabetic supply
    Products Affectedmixed
    DIACOMITlisted product
    Products Affectedmixed
    fidaxomicinlisted product (Dificid)
    Products listed (drug/formulation)mixed
    FRUZAQLA ORAL CAPSULE 1 MG, 5 MGProduct listing as provided
    Products listed (drug/formulation)mixed
    FYCOMPA ORAL TABLET 10 MG, 12 MG, 2 MG, 4 MG, 6 MG, 8 MGProduct listing as provided
    perampanel oral suspensionProduct listing as provided
    perampanel oral tablet 10 mg, 12 mg, 2 mg, 4 mg, 6 mg, 8 mgProduct listing as provided
    Products listed (drug/formulation)mixed
    GATTEX 30-VIALProduct listing as provided
    GATTEX ONE-VIALProduct listing as provided
    Products listed (drug/formulation)mixed
    CERDELGAProduct listing as provided
    miglustatProduct listing as provided
    Other products listed in excerptmixed
    GABARONEProduct listing
    GAVRETOProduct listing
    GILOTRIFProduct listing
    FOTIVDAProduct listing (mentioned)
    Products Affected (Ibrance)mixed
    IBRANCE ORAL CAPSULE 125 MGIbrance product listed
    IBRANCE ORAL TABLETIbrance product listed
    Products Affected (Imbruvica)mixed
    IMBRUVICA ORAL CAPSULE 140 MGImbruvica product listed
    IMBRUVICA ORAL CAPSULE 70 MGImbruvica product listed
    IMBRUVICA ORAL SUSPENSIONImbruvica product listed
    IMBRUVICA ORAL TABLETImbruvica product listed
    Products listed (medication names)mixed
    INBRIJA INHALATION CAPSULEproduct listed
    Products listed (medication names)mixed
    TOBI PODHALERproduct listed
    Products listed (medication names)mixed
    INCRELEXproduct listed
    Products listed (medication names)mixed
    INREBICproduct listed
    Products listed (medication names)mixed
    IMPAVIDOproduct listed
    Ejection fraction — Corlanor
    Ejection fraction (EF)Left ventricular EF ≤ 35% required for Corlanor initiation
    ContextMust be for heart failure in adults and documented in medical record
    Prescriber

    Definitions and Background

    Alpha-1 proteinase inhibitor (A1-PI) deficiency is a congenital disorder that can result in early-onset emphysema. For members with severe congenital A1-PI deficiency who have clinically evident emphysema, augmentation therapy with plasma‑derived A1-PI products may be authorized when specific clinical documentation is provided. The PA submission must include the diagnosis, patient weight, the A1-PI genotype/phenotype characterization and measured baseline A1-PI level to document severity. Prescriptions for AAT augmentation products must be written by a pulmonologist, and authorized therapy is approved for a maximum duration of 1 year per the policy.

    A1-PI phenotype / baseline level
    A1-PI phenotype/phenotypingGenotype/phenotype characterization required to document severity of A1-PI deficiency
    Baseline A1-PI levelMeasured baseline alpha-1 proteinase inhibitor (A1-PI) level required
    Required documentationDiagnosis of severe congenital A1-PI deficiency with clinically evident emphysema and patient weight must be submitted
    LEMS confirmation — required diagnostic tests

    Policy Revision History

    8/1/2026prior_authorization_effective_dateLatest

    Prior authorization criteria for the listed products became effective; prerequisite therapy requirements are variably applied depending on product.

    Policy Summary
    PayerHealth Alliance Plan (HAP)
    PolicyAAT deficiency therapies prior authorization
    Policy CodePolicy N/A
    Change TypeNo material changes
    Effective DateAug 1, 2026
    Next Review DateN/A
    Key ActionSubmit prior authorization with diagnosis, weight, A1-PI phenotype and baseline A1-PI level; prescription must be written by a pulmonologist.
    SourceLink
    On This Page
    Coverage Criteria and Product-Specific Prior AuthorizationActions Required by Prescribers / Denial RisksAffected Products and CodingDefinitions and BackgroundPolicy Revision History
    Entries note PA criteria, indications 'All Medically-accepted Indications', and variable prerequisite therapy or Part B prerequisites; review specific product entries for details
    GAVRETO: Prescription must be written by an oncologist or pulmonologist; diagnosis of NSCLC or thyroid cancer verified by an FDA-approved diagnostic test for RET fusions; coverage duration 5 years
    Prior Authorization

    Firdapse prior authorization and diagnostic confirmation

    Firdapse (amifampridine) requires prior authorization and must be prescribed by a neurologist; submit electrodiagnostic testing (repetitive nerve stimulation) and anti‑P/Q‑type VGCC antibody testing to confirm Lambert‑Eaton diagnosis. Coverage is for 1 year.

    • Prescriber must be a neurologist.
    • Provide electrodiagnostic studies and anti‑P/Q‑type VGCC antibody testing.
    Documentation Required

    ARIKAYCE — submit sputum culture and prior multidrug therapy documentation

    For ARIKAYCE prior authorization, submit medical records including sputum culture confirming Mycobacterium avium complex (MAC) lung disease and documentation of failure to obtain negative sputum cultures after ≥6 months of a multidrug background regimen.

    • Prescriber must be or consult with an infectious disease specialist or pulmonologist.
    • Include sputum culture results and ≥6 months of prior multidrug therapy documentation.
    Prior Authorization

    ATTRUBY prescriber restriction and required diagnostic confirmation

    ATTRUBY requires prior authorization and the prescription must be written by a cardiologist; include confirmation of diagnosis with appropriate testing. Coverage is for 1 year.

    • Prescription must be written by a cardiologist.
    • Provide diagnostic confirmation documentation.
    Step Therapy

    Document prior therapy trials when prerequisite therapy is required

    Some products in this document require documentation of prior therapy trials (Prerequisite Therapy: Yes); when indicated, prior therapy failure or intolerance must be documented before approval.

    • When an entry lists Prerequisite Therapy: Yes, include clinical records showing trials and outcomes of specified prior agents.
    Note

    Products that indicate no prerequisite therapy

    Where the product entry indicates no prerequisite therapy, prior therapy trials are not required for approval but prior authorization criteria and required documentation still apply.

    Step Therapy

    Antidepressant step‑therapy: document two prior antidepressant trials

    For listed antidepressants used to treat major depressive disorder, the member must have tried two generic antidepressants from different classes (e.g., SSRIs, SNRIs, TCAs, bupropion) before certain agents will be approved; document the trials and outcomes.

    • List the two different generic antidepressants tried and reason for failure/intolerance.
    • Include dates and doses of prior trials.
    Step Therapy

    Antipsychotic step‑therapy: document two atypical antipsychotic failures

    For listed antipsychotics treating bipolar disorder or schizophrenia, prior authorization requires documentation of treatment failure with two atypical antipsychotics (or rationale why alternatives are unsuitable); include treatment history.

    • Document the two atypical antipsychotics tried and reasons for failure.
    • Provide diagnosis and treatment timeline.
    Step Therapy

    Document trials of required alternatives per step‑therapy rules

    When step therapy is specified, providers must document trial and failure (or contraindication) of the required alternative agents or formulations before requesting the listed product.

    • Provide clinical notes showing trials, durations, and outcomes of alternative agents.
    • If dosing frequency escalation is requested (e.g., Cosentyx every‑2‑week dosing), document failure of the lower‑frequency regimen.
    Prior Authorization

    Oncology products — PA, prescriber restrictions, and diagnostic testing

    Prior authorization is required for many oncology agents in this section; prescriptions generally must be written by or in consultation with an oncologist and include diagnosis documentation and any diagnostic testing required (e.g., PDGFRA mutation for GIST, RET fusion testing). Coverage durations are listed per product (commonly 5 years).

    • Ensure prescriber specialty matches the product's restriction (oncologist, hematologist, cardiologist, etc.).
    • Include disease‑specific diagnostic testing when specified (e.g., PDGFRA D842V, RET fusions).
    Prior Authorization

    Examples: BALVERSA and BRAFTOVI — oncologist prescription and diagnosis documentation required

    Examples: BALVERSA, BRAFTOVI and similar oncology agents require prior authorization with prescription by an oncologist and are typically authorized for up to 5 years; include documented diagnosis and any specified biomarker testing.

    • Confirm prescriber is an oncologist.
    • Attach diagnostic reports and biomarker test results.
    Prior Authorization

    BENLYSTA Subcutaneous — prescriber restriction and documentation

    BENLYSTA Subcutaneous requires prior authorization; prescriber should be a rheumatologist or nephrologist and required documentation includes diagnosis, autoantibody testing, prior therapies and responses. Coverage duration is 3 years.

    • Provide autoantibody test results and prior treatment history with outcomes.
    • Confirm prescriber specialty (rheumatologist or nephrologist).
    Prior Authorization

    BRIVIACT — PA with prerequisite therapy noted

    Brivaracetam (BRIVIACT) requires prior authorization with prerequisite therapy noted as 'Yes'; include age‑appropriate information per FDA labeling and documentation of prior therapy trials and response.

    • Provide prior anticonvulsant trial history and response.
    • Confirm beneficiary age per FDA labeling.
    Documentation Required

    Targeted oncology agents — prescriber and baseline testing requirements

    CABOMETYX, CALQUENCE, CAPRELSA and similar targeted agents require prior authorization; ensure the prescriber is or consults with an oncologist and submit required baseline testing where specified (e.g., ECG/electrolytes/TSH for CAPRELSA).

    • Attach diagnostic and baseline monitoring tests as listed for each product.
    • Confirm oncologist prescriber or consult note.
    Prior Authorization

    CINQAIR — prescriber restriction, baseline testing, and administration setting

    CINQAIR (reslizumab) requires prior authorization with prescriber restricted to pulmonology or immunology, baseline testing including allergen test and FEV1 measures, and administration must occur in a setting prepared to manage anaphylaxis (self‑administration will not be approved).

    • Do not request self‑administration; document plan for supervised administration.
    • Provide allergen test, baseline FEV1 and post‑bronchodilator FEV1, asthma history, and baseline eosinophil count.
    Documentation Required

    COBENFY — document diagnosis and treatment history

    COBENFY (and COBENFY STARTER PACK) prior authorization requests must include documentation of diagnosis and treatment history; prerequisite therapy is required for some indications and coverage duration is commonly 5 years.

    • Include treatment history demonstrating prior trials and outcomes.
    • Document beneficiary age per FDA labeling.
    Prescription must be written by a cardiologist
    Heart rate — Corlanor
    Heart rate (HR)Resting HR ≥ 70 beats per minute required for Corlanor initiation
    Rhythm requirementPatient must be in sinus rhythm
    Concomitant therapyPatient should be on maximally tolerated beta-blocker or have documented contraindication
    Cyclobenzaprine age threshold
    Age thresholdPatients aged < 65 years: approved
    Older adultsPatients aged ≥ 65 years: additional criteria must be met; medical records documenting diagnosis required
    DocumentationMedical records documenting diagnosis required for all requests
    Baseline eosinophil count
    Baseline eosinophil countEosinophil count ≥ 150 cells/mcL required (within previous 12 months for certain indications)
    Use caseSpecified for DUPIXENT and FASENRA severe asthma approvals
    TimingCount must be documented within the prior 12 months when specified
    Pre-treatment hemoglobin — ESAs
    Pre-treatment hemoglobin (Hb)Pre-treatment Hb < 10 g/dL required prior to initiating erythropoiesis stimulating agents (ESAs)
    Renewal criteriaRenewal rules vary by indication (see ESA renewal criteria)
    ExclusionsUncontrolled hypertension and pure red cell aplasia after ESA treatment are exclusions
    Ferritin — ESAs
    Ferritin thresholdFerritin > 100 mcg/L defines adequate iron stores prior to ESA initiation
    PurposeRequired to confirm iron repletion before ESA therapy
    Related labsFerritin is considered alongside transferrin saturation to define adequate iron stores
    Transferrin saturation — ESAs
    Transferrin saturation (TSAT)TSAT > 20% defines adequate iron stores prior to ESA initiation
    Complementary criterionCan be used alternatively to ferritin >100 mcg/L to demonstrate adequate iron stores
    Clinical implicationMust rule out other causes of anemia before ESA initiation
    Baseline eosinophil count (FASENRA)
    Baseline eosinophil count for FASENRABaseline eosinophil count ≥ 150 cells/mcL within the previous 12 months required for severe asthma indication
    DocumentationAllergen test, baseline and post-bronchodilator FEV1, and asthma history must also be provided
    PrescriberPrescriber must be a pulmonologist, immunologist, allergist, or rheumatologist
    Baseline platelet count — INREBIC
    Baseline platelet countDocumented baseline platelet count ≥ 50,000 per cubic millimeter required prior to INREBIC initiation
    Thiamine requirementBaseline thiamine level must be evaluated and repleted prior to initiation if deficient
    PrescriberMust be prescribed by a hematologist/oncologist
    Confirmatory testsElectrodiagnostic studies including repetitive nerve stimulation and anti-P/Q-type VGCC antibody testing required to confirm LEMS
    PrescriberPrescription must be written by a neurologist
    DocumentationDocumented diagnosis with supporting electrodiagnostic and antibody testing required
    ALK-positive NSCLC — definition for Alunbrig
    Definition of ALK-positive NSCLCMetastatic non-small cell lung cancer that is ALK-positive as detected by an approved test
    PrescriberMust be prescribed by or in consultation with an oncologist
    Coverage durationApprove for up to 5 years; continuation of prior therapy allowed
    Castration-resistant metastatic prostate cancer with BRCA mutation — Akeega
    Clinical definitionMetastatic prostate cancer that is castration-resistant with deleterious or suspected deleterious BRCA mutation
    PrescriberMust be prescribed by an oncologist or urologist
    Coverage durationApprove for up to 5 years
    Severe active lupus nephritis — BENLYSTA exclusion
    Severe active lupus nephritisListed exclusion for BENLYSTA SUBCUTANEOUS (use in severe active lupus nephritis or active CNS involvement may lead to denial)
    Required infoDiagnosis, autoantibody testing, and prior treatments including response must be provided
    PrescriberPrescription must be written by a rheumatologist or nephrologist
    Corlanor heart failure criteria — EF and HR thresholds
    Corlanor EF thresholdLeft ventricular ejection fraction ≤ 35% required
    Corlanor HR thresholdHeart rate ≥ 70 beats per minute required
    Additional requirementsPatient must be in sinus rhythm and on maximally tolerated beta-blocker or have contraindication
    Cosentyx prerequisite therapy — DMARD/trial requirements
    Prerequisite therapy (arthritis)Trial of one non-biologic DMARD required before Cosentyx for arthritis indications
    Plaque psoriasis requirementTrial and failure of cyclosporine and methotrexate for at least 3 months required
    Dosing noteEvery 2-week Cosentyx dosing requires prior failure of 4-week dosing
    Corneal cystine crystal — Cystadrops initiation requirement
    Corneal cystine crystalDocumentation of presence of corneal cystine crystal required to start Cystadrops
    PrescriberPrescribing limited to ophthalmologist or corneal specialist
    AgeBeneficiary must be of appropriate age per FDA labeling
    Clostridium difficile diagnosis — fidaxomicin
    Diagnosis requirementDocumented diagnosis of Clostridium difficile required for fidaxomicin coverage
    PrescriberMust be prescribed by or in consultation with an infectious disease specialist
    Coverage durationCoverage duration: 1 month
    Baseline eosinophil count — DUPIXENT and FASENRA
    Baseline eosinophil (DUPIXENT)Eosinophil count ≥ 150 cells/mcL within prior 12 months required for certain DUPIXENT asthma approvals
    Baseline eosinophil (FASENRA)Baseline eosinophil ≥ 150 cells/mcL within previous 12 months required for severe asthma indication
    DocumentationEosinophil counts and indication-specific supporting data must be provided in medical record
    Adequate iron stores — ESA definition
    Adequate iron stores definitionFerritin > 100 mcg/L OR transferrin saturation > 20% defines adequate iron stores prior to ESA initiation
    Pre-treatment HbPre-treatment hemoglobin < 10 g/dL required for ESA initiation
    ExclusionsUncontrolled hypertension and pure red cell aplasia after ESA treatment are exclusions
    Prescriber Restrictions — summary
    Specialist prescriber requirementMany products require prescription by or consultation with a specialist appropriate to the indication (e.g., pulmonologist, oncologist, cardiologist, neurologist)
    ExamplesCorlanor: cardiologist; ARIKAYCE: infectious disease specialist or pulmonologist; INBRIJA: neurologist; IMBRUVICA: oncologist/hematologist/transplant specialist
    Denial riskFailure to meet prescriber restriction may result in denial of PA
    Continuation — note about continuation requests
    Continuation requestsContinuation/renewal requires documentation of prior response to therapy as specified per product (e.g., INBRIJA, ESAs, INREBIC, Epidiolex)
    ExamplesINBRIJA: prior response to levodopa inhalation if continuation; ESAs: criteria for renewal tied to Hb thresholds and response
    DocumentationMedical records must show treatment response for continuation approvals